Gastric Cancer Clinical Trials

73 studies are recruiting for gastric cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

   Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells. Objective: To see if anti-KRAS G12 V mTCR cells are safe …

   Stage

   Phase 1

   Ages

   18 to 72

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03190941 on ClinicalTrials.gov

2. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSD, La Jolla, California

   Locations

   54 in total

   Run by

   Genmab

   See if you can join NCT03526835 on ClinicalTrials.gov

3. Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

   This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT07124351 on ClinicalTrials.gov

4. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors.…

   Stage

   Phase 1

   Ages

   19 and older

   Site

   University of Arkansas Medical School, Little Rock, Arkansas

   Locations

   20 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

5. Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

   Objective: To follow people with GISTs and collect tumor tissue so that it can be studied in the lab. Eligibility: People age 6 and older who have a GIST. Design: Participants will be screened with a review of their medical records and samples. Participants will enroll in 1 other NIH study, and may…

   Stage

   Not phased

   Ages

   6 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04557969 on ClinicalTrials.gov

6. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

   Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. [18F]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers …

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06503146 on ClinicalTrials.gov

7. KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

   This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to tre…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Rutgers Cancer Institute, New Brunswick, New Jersey

   Locations

   2 in total

   Run by

   Christian Hinrichs

   See if you can join NCT05483491 on ClinicalTrials.gov

8. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

9. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   VA Greater Los Angeles Healthcare System, Los Angeles, California

   Locations

   16 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

10. [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

    This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast can…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Locations

    2 in total

    Run by

    Blue Earth Diagnostics

    See if you can join NCT07432633 on ClinicalTrials.gov

11. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    96 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

12. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

    This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminar…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI at Florida Cancer Specialists, Orlando, Florida

    Locations

    6 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07807345 on ClinicalTrials.gov

13. A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

    This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The stud…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    3 in total

    Run by

    SHY Therapeutics

    See if you can join NCT07705334 on ClinicalTrials.gov

14. Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

    This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Partici…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Duarte, Duarte, California

    Locations

    3 in total

    Run by

    BigHat Biosciences, Inc.

    See if you can join NCT07529808 on ClinicalTrials.gov

15. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

    The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Phoenix, Arizona

    Locations

    314 in total

    Run by

    AstraZeneca

    See if you can join NCT07431281 on ClinicalTrials.gov

16. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest /ID# 283487, Grand Rapids, Michigan

    Locations

    3 in total

    Run by

    AbbVie

    See if you can join NCT07807956 on ClinicalTrials.gov

17. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Denver, Colorado

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

18. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama Birmingham, Birmingham, Alabama

    Locations

    26 in total

    Run by

    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

19. Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

    Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Harry S Truman Veterans Memorial Hospital, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT03551951 on ClinicalTrials.gov

20. A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

    This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocar…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    27 in total

    Run by

    Toray Industries, Inc

    See if you can join NCT06038578 on ClinicalTrials.gov

21. Distance-Based Exercise to Preserve Function and Prevent Disability

    This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side e…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Kaiser Permanente Dublin, Dublin, California

    Locations

    23 in total

    Run by

    Alliance for Clinical Trials in Oncology

    See if you can join NCT07059884 on ClinicalTrials.gov

22. AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

    The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Research Site, Orange, California

    Locations

    52 in total

    Run by

    AstraZeneca

    See if you can join NCT06219941 on ClinicalTrials.gov

23. IKS014 in Advanced Solid Tumors That Express HER2

    This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Locations

    13 in total

    Run by

    Iksuda Therapeutics Ltd.

    See if you can join NCT05872295 on ClinicalTrials.gov

24. Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

    This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Jacksonville, Florida

    Locations

    25 in total

    Run by

    AstraZeneca

    See if you can join NCT06005493 on ClinicalTrials.gov

25. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Precision NextGen Oncology, Beverly Hills, California

    Locations

    8 in total

    Run by

    Neonc Technologies, Inc.

    See if you can join NCT06047379 on ClinicalTrials.gov